Dosage Forms & Drug Delivery Systems – Page 41

Pet Failure in otic suspension filling: packaging integrity and stability justification

Identifying symptoms of pet failure in otic suspension filling is the first step toward resolution. Common signals may include:Click to read the full article.

Assay Oos after supplier change: sanitation, water, and EM checks

The initial indication that a problem exists often arises from in-process controls or final product testing. Symptoms or signals may include:Click to read the full article.

Microbial Limits Failure in ear drop manufacturing: sanitation, water, and EM checks

Symptoms of microbial limits failures may present themselves through various pathways, including but not limited to:Click to read the full article.

Assay Oos during inspection readiness: packaging integrity and stability justification

The first step in addressing assay OOS during inspection readiness is recognizing the symptoms and signals that indicate potential issues. Below are common symptoms that may arise:Click to read the…

Ph Drift after supplier change: GMP documentation for FDA/EMA/MHRA review

The initial signals that suggest a potential issue with pH drift include:Click to read the full article.

Hold Time Bioburden Rise after supplier change: sanitation, water, and EM checks

The first step in managing a bioburden rise is recognizing the symptoms that indicate a potential issue. Symptoms may manifest as:Click to read the full article.

Sedimentation Oos in ear drop manufacturing: GMP documentation for FDA/EMA/MHRA review

The first step in addressing sedimentation OOS in ear drop manufacturing is to promptly recognize the symptoms or signals that indicate a potential failure in the production process. Symptoms may…

Leakage Complaint during bulk hold: investigation steps with CAPA evidence

Recognizing the symptoms or signals indicative of a leakage complaint is crucial for initiating an investigation. The following observations may signal a potential leakage issue:Click to read the full article.

Microbial Limits Failure after supplier change: GMP documentation for FDA/EMA/MHRA review

The first step in addressing a microbial limits failure is recognizing the symptoms that may indicate a problem. Common signs include:Click to read the full article.

Microbial Limits Failure during line setup: GMP documentation for FDA/EMA/MHRA review

The first step in addressing a microbial limits failure is to identify the symptoms or signals that indicate a deviation. Typical signals may include:Click to read the full article.

Ph Drift during method transfer: manufacturing vs lab root cause decision tree

Identifying symptoms of pH drift promptly can prevent larger quality issues from arising. Common signals observed during method transfer include:Click to read the full article.

Control Strategy Weakness for long-acting injectables: regulatory-ready investigation and CAPA plan

Recognizing symptoms or signals indicative of control strategy weaknesses is the first step in an effective investigation. Symptoms may manifest at various stages of manufacturing or quality control processes. Key…